title: Topical minocycline foam for moderate to severe acne vulgaris: Phase 2 randomized double-blind, vehicle-controlled study results.
authors.affiliation: The Chaim Sheba Medical Center, Affiliated with Tel-Aviv University, Sackler School of Medicine, Tel Aviv, Israel.
authors.forename: Avner
authors.initials: A
authors.lastname: Shemer
authors.affiliation: Clalit Health Services Clinic, Tel Aviv, Israel.
authors.forename: Joseph
authors.initials: J
authors.lastname: Shiri
authors.affiliation: Department of Dermatology, Pediatric Dermatology Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
authors.forename: Jacob
authors.initials: J
authors.lastname: Mashiah
authors.affiliation: Dermatology Department, Hospital Nossa Senhora da Saúde (Gamboa), Rio de Janeiro, Brazil.
authors.forename: Renata
authors.initials: R
authors.lastname: Farhi
authors.affiliation: Department of Medicine, University of Toronto, and Mediprobe Research Inc, London, Ontario, Canada. Electronic address: agupta@execulink.com.
authors.forename: Aditya K
authors.initials: AK
authors.lastname: Gupta
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy*; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D005148:Facial Dermatoses / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008911:Minocycline / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D008911:Minocycline